胃癌患者术后延长随访的可行性
该研究基于韩国国民健康保险索赔数据,纳入术后5年无复发或第二原发癌的胃癌患者40468例,比较5年后定期随访与不规律随访与总生存及复发后生存的关系。定期随访与15年总死亡率降低(49.4%至36.9%)及复发后5年生存率提高(32.7%至71.1%)相关,内镜联合腹盆腔CT的复发后5年生存率最高(74.5%)。
要点
- 术后5年定期随访与15年总死亡率由49.4%降至36.9%相关(P<.001)。
- 晚期复发或残胃癌后5年生存率由32.7%升至71.1%(P<.001)。
- 内镜联合腹盆腔CT的5年复发后生存率74.5%,高于单用内镜54.5%或单用CT 47.1%。
核心结论
- 这些发现提示术后5年后的延长定期随访应在临床实施,并应重新考虑当前胃癌术后随访方案的做法与价值。
研究设计与样本
- 基于韩国国民健康保险索赔数据的群体性回顾性队列研究,数据提取自2005年1月1日至2014年12月31日,随访数据截至2021年12月31日。
- 纳入术后5年无复发或其他癌症的胃癌患者40468例,分为定期随访组14294例与不规律随访组26174例。
- 数据分析时间为2023年8月15日至11月15日。
主要发现
- 定期随访组平均(SD)年龄61.3(11.7)岁,男性9669例(67.8%);不规律随访组平均(SD)年龄58.1(11.1)岁,男性18007例(68.8%)。
- 晚期复发或残胃癌共3138例(7.8%),其中术后5至10年1610/40468例(4.0%),术后10年后1528/16287例(9.4%)。
- 定期随访与术后5年总死亡率显著降低相关(15年死亡率由49.4%降至36.9%;P<.001)。
- 定期随访与晚期复发或残胃癌发生后复发后生存率显著改善相关(5年复发后生存率由32.7%升至71.1%;P<.001)。
- 随访方法比较显示,内镜联合腹盆腔CT(全胃切除亚组仅腹盆腔CT)的5年复发后生存率最高(单用内镜 vs 单用腹盆腔CT vs 两者联合分别为54.5% vs 47.1% vs 74.5%)。
临床怎么用
- 作者认为术后5年后的延长定期随访应在临床实施,并应重新考虑当前胃癌术后随访方案的做法与价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Conventional research and guidelines on postgastrectomy follow-up for gastric cancer often restrict their focus to the first 5 years after surgery. OBJECTIVE: To evaluate the association of extended regular follow-up after 5 years postgastrectomy in patients with gastric cancer with overall and postrecurrence survival rates. DESIGN, SETTING, AND PARTICIPANTS: This population-based, retrospective cohort study used Korean National Health Insurance claims data extracted between January 1, 2005, and December 31, 2014, with follow-up data examined until December 31, 2021. Patients without recurrence or other cancers at 5 years postgastrectomy were divided into 2 groups: those who had extended regular follow-up visits and those who did not. The data were analyzed between August 15 and November 15, 2023. EXPOSURES: Regular follow-up vs irregular follow-up after 5 years postgastrectomy. MAIN OUTCOMES AND MEASURES: The main outcome was whether extended regular follow-up after 5 years postgastrectomy was independently associated with overall and postrecurrence survival rates using Cox proportional hazards regression. Postrecurrence survival rates were also compared across different follow-up methods and intervals. RESULTS: A total of 40 468 patients with gastric cancer were included, with 14 294 in the regular follow-up group (mean [SD] age, 61.3 [11.7] years; 9669 male [67.8%]) and 26 174 in the irregular follow-up group (mean [SD] age, 58.1 [11.1] years; 18 007 male [68.8%]). Late recurrence or gastric remnant cancer (GRC) was identified in 3138 patients (7.8%), including 1610 of 40 468 patients (4.0%) between 5 and 10 years postgastrectomy and 1528 of 16 287 (9.4%) patients after 10 years postgastrectomy. Regular follow-up was associated with a significantly decreased overall mortality rate after 5 years postgastrectomy (from 49.4% to 36.9% in 15-year mortality rate; P < .001), as well as significant improvement of postrecurrence survival rate after occurrence of late recurrence or GRC (from 32.7% to 71.1% in 5-year postrecurrence survival rate; P < .001). Comparison of follow-up methods revealed that the combination of endoscopy and abdominopelvic computed tomography (CT) (only abdominopelvic CT in total gastrectomy subgroup) yielded the highest 5-year postrecurrence survival rate (endoscopy alone vs abdominopelvic CT alone vs a combination of both, 54.5% vs 47.1% vs 74.5%, respectively). A time interval of more than 2 years between previous endoscopy or abdominopelvic CT and late recurrence and GRC diagnosis was associated with a significantly reduced postrecurrence survival rate (hazard ratio, 1.72 [95% CI, 1.45-2.04] and 1.48 [95% CI, 1.25-1.75], respectively). CONCLUSIONS AND RELEVANCE: These findings suggest that extended regular follow-up after 5 years postgastrectomy should be implemented clinically and that current practice and value of follow-up protocols in postoperative care of patients with gastric cancer be reconsidered.
引用
- Lee JH, Kim J, Choi JY, et al. Feasibility of Extended Postoperative Follow-Up in Patients With Gastric Cancer. JAMA Surg. 2024. PMID: 38888902. doi:10.1001/jamasurg.2024.1753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。